EATONTOWN, N.J., Oct. 7 /PRNewswire/ -- Roberts Pharmaceutical Corporation
(Nasdaq: RPCX) announced today the election of Dr. Zola P. Horovitz to its
Board of Directors.  The election of Dr. Horovitz fills the vacancy created by
the recent passing of W. Robert Fowler, M.D., a long standing member of the
Roberts Board.
    Dr. Horovitz's distinguished career includes 35 years pharmaceutical
experience in senior management, research, and scientific positions with
Bristol-Myers Squibb and The Squibb Institute for Medical Research.  He
retired from Bristol-Myers Squibb in 1994 after serving as Vice President of
Business Development and Planning and, prior to that, as Vice President of
Licensing.  At The Squibb Institute for Medical Research, he held several
senior positions including Vice President of Research Planning & Scientific
Liaison; Vice President of Drug Development; and Associate Director of R&D.
As Director of the Department of Pharmacology at  The Squibb Institute, he was
responsible for the research program leading to the development of the ACE
inhibitor captopril, for which he received the American Heart Association's
Discovery Award.  Dr. Horovitz is also a recipient of the A.E. Bennett
Neuropsychiatric Research Award for original investigation in biological
psychiatry.  He received a Ph.D. in Pharmacology and holds a Distinguished
Alumni Award from the University of Pittsburgh.  Dr. Horovitz has published
over 90 books, articles, and abstracts.  Among is his many professional and
civic activities, Dr.  Horovitz is a Fellow of the American Foundation for
Pharmaceutical Education and recently served as Commissioner of the New Jersey
Cancer Research Commission.
    Dr. Robert A. Vukovich, President and CEO of Roberts, said "We are
delighted to have such an eminently qualified professional as Dr. Horovitz
join our Board of Directors.  All of us at Roberts look forward to his input
and guidance."  Dr. Horovitz noted, "With the recent U.S. marketing clearance
of Roberts first pipeline drug ProAmatine(TM) and, with the potential near
term approval of Agrelin(R), this is an exciting period for the Company.  I
look forward to actively sharing in that excitement."
    Roberts Pharmaceutical Corporation is an international pharmaceutical
company focusing on the acquisition and development of late-stage drugs.
Roberts currently markets its products in seven countries and has operating
subsidiaries in the U.S., Canada, and the United Kingdom.
    This and past news releases by Roberts Pharmaceutical Corporation are
available through PR Newswire's Company News On-Call fax service at
1-800-758-5804, extension 760975 and on the internet at
http//www.prnewswire.com
    This release may contain forward-looking statements which reflect
management's current views of future events and operations.  These forward-
looking statements are based on assumptions and external factors, including
assumptions relating to regulatory action and competing products.  Any changes
in such assumptions or external factors could produce significantly different
results.

Link to this page: